SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

Search

Sanofi SA

Closed

SectorHealthcare

92.06 2.59

Overview

Share price change

24h

Current

Min

89.74

Max

92.08

Key metrics

By Trading Economics

Income

1.4B

1.9B

Sales

3B

11B

P/E

Sector Avg

18.265

56.602

EPS

1.79

Dividend yield

4.22

Profit margin

17.65

Employees

82,878

EBITDA

2.2B

2.8B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+30.33% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.22%

2.45%

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-19B

111B

Previous open

89.47

Previous close

92.06

News Sentiment

By Acuity

43%

57%

150 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sanofi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2025, 11:29 UTC

Acquisitions, Mergers, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5 maj 2025, 09:09 UTC

Acquisitions, Mergers, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5 maj 2025, 07:25 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

15 maj 2025, 11:04 UTC

Market Talk
Earnings

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13 maj 2025, 12:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13 maj 2025, 10:23 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13 maj 2025, 08:58 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12 maj 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 maj 2025, 17:55 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 maj 2025, 15:12 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6 maj 2025, 06:16 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's Polish Business Disposal Is Attractive -- Market Talk

6 maj 2025, 06:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5 maj 2025, 14:11 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5 maj 2025, 11:30 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5 maj 2025, 06:48 UTC

Acquisitions, Mergers, Takeovers

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5 maj 2025, 06:48 UTC

Acquisitions, Mergers, Takeovers

Santander Will Own 13% of Santander Polska Following Transaction

5 maj 2025, 06:47 UTC

Acquisitions, Mergers, Takeovers

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5 maj 2025, 06:46 UTC

Acquisitions, Mergers, Takeovers

Santander Expects EUR2B Net Capital Gain From Deal

5 maj 2025, 06:46 UTC

Acquisitions, Mergers, Takeovers

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5 maj 2025, 06:45 UTC

Acquisitions, Mergers, Takeovers

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

5 maj 2025, 06:45 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Reduce 2025 Dividend Payout to Maximum of 10% of Net Profit

5 maj 2025, 06:45 UTC

Acquisitions, Mergers, Takeovers

Erste Group: Dividend for 2024 Remains Unchanged at EUR3 a Share

5 maj 2025, 06:44 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Temporarily Reduce Dividend Payout

5 maj 2025, 06:43 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Cancel Planned EUR700M Buyback

5 maj 2025, 06:42 UTC

Acquisitions, Mergers, Takeovers

Erste Group Will Fund the Acquisition Exclusively From Internal Resources

5 maj 2025, 06:40 UTC

Acquisitions, Mergers, Takeovers

Santander Says It Plans to Distribute EUR3.2B Through Buybacks

5 maj 2025, 06:39 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Buy 49% of Santander Polska's for PLN584 a Share

5 maj 2025, 06:38 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Buy 49% Stake in Poland Unit of Banco Santander

5 maj 2025, 06:37 UTC

Acquisitions, Mergers, Takeovers

Erste Group to Become No. 3 Bank in Poland Through Deal

5 maj 2025, 06:36 UTC

Acquisitions, Mergers, Takeovers

Erste Group Also Acquires 50% in Asset Management Firm Santander TFI for EUR200M

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

30.33% upside

12 Months Forecast

Average 115.786 EUR  30.33%

High 127 EUR

Low 95 EUR

Based on 15 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

150 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.